Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Phase 1

Recruiting

• Conditions: Advanced Cancer; Metastatic Cancer; Malignant Neoplastic Disease
• Interventions: Drug: MRTX849; Drug: Pembrolizumab; Drug: Cetuximab; Drug: Afatinib

• Registration Number: NCT03785249
• Lead Sponsor: Mirati Therapeutics Inc.

Brief Summary

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

Detailed Description

This study will evaluate the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 (adagrasib) is an orally-available small molecule inhibitor of KRAS G12C.

Study Timeline

• Study First Submitted: 2018-12-18
• Study First Submitted QC: 2018-12-19
• Study First Posted: 2018-12-24
• Study Start: 2018-12-26
• Status Verified: 2024-06
• Last Update Submitted: 2024-06-18
• Last Update Posted: 2024-06-21
• Primary Completion: 2025-07-31
• Study Completion: 2026-01-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 822

Inclusion Criteria

• Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation
• Unresectable or metastatic disease
• Standard treatment is not available or patient declines; first-line treatment for NSCLC for certain cohorts
• Adequate organ function

Read More

Exclusion Criteria

• History of intestinal disease or major gastric surgery or inability to swallow oral medications
• Other active cancer

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Phase 1 Dose Exploration	MRTX849	Dose escalation of MRTX849 to determine maximum tolerated dose
Phase 1b Expansion	MRTX849	Expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 to recommend Phase 2 regimens
Phase 2	MRTX849	Separate cohorts of patients stratified by histological diagnosis, prior treatment history or co-mutation status (e.g., STK11) for evaluation of clinical activity of MRTX849
Pilot Phase 1b Combination with Pembrolizumab	MRTX849	Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with pembrolizumab in patients with NSCLC
Pilot Phase 1b Combination with Pembrolizumab	Pembrolizumab	Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with pembrolizumab in patients with NSCLC
Pilot Phase 1b Combination with Cetuximab	MRTX849	Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with CRC
Pilot Phase 1b Combination with Cetuximab	Cetuximab	Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with CRC
Pilot Phase 1b Combination with Afatinib	MRTX849	Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with afatinib in patients with NSCLC
Pilot Phase 1b Combination with Afatinib	Afatinib	Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with afatinib in patients with NSCLC
Phase 2 Combination with Cetuximab	MRTX849	Phase 2 evaluation of the clinical activity of MRTX849 in combination with cetuximab in patients with CRC
Phase 2 Combination with Cetuximab	Cetuximab	Phase 2 evaluation of the clinical activity of MRTX849 in combination with cetuximab in patients with CRC
Pilot Phase 1b Combination with Cetuximab in NSCLC	MRTX849	Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with NSCLC
Pilot Phase 1b Combination with Cetuximab in NSCLC	Cetuximab	Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with NSCLC
Pilot Phase 1b Combination with Cetuximab in PDAC	MRTX849	Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with pancreatic adenocarcinoma (PDAC)
Pilot Phase 1b Combination with Cetuximab in PDAC	Cetuximab	Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with pancreatic adenocarcinoma (PDAC)

Primary Outcome Measures

Name	Time	Method
Characterize the safety of MRTX849 in patients having advanced solid tumor malignancies with KRAS G12C mutation	20 months	Number of participants with treatment related adverse events
Evaluate the pharmacokinetics of MRTX849	20 months	Blood plasma concentration
Evaluate clinical activity/efficacy of MRTX849	20 months	Objective response rate in accordance with Response Evaluation Criteria in Solid Tumors (RECIST)

Secondary Outcome Measures

Name	Time	Method
Establish maximum tolerated dose	12 months	Number of participants with dose limiting toxicity
Characterize safety and tolerability of MRTX849 in combination with selected therapeutic agents	12 months	Number of participants with dose limiting toxicity
Evaluate the pharmacokinetics of new MRTX849 oral formulations	6 months	Blood plasma concentration
Evaluate the pharmacokinetics of MRTX849 administered with food	6 months	Blood plasma concentration

Trial Locations

Locations (214)

Local Institution - 001-873-A; 🇺🇸 Tucson, Arizona, United States

Local Institution - 001-840-B; 🇺🇸 Bellflower, California, United States

Local Institution - 001-850-K; 🇺🇸 Dublin, California, United States

Local Institution - 001-840-C; 🇺🇸 Harbor City, California, United States

Local Institution - 001-850-B; 🇺🇸 Oakland, California, United States

Local Institution - 001-850-C; 🇺🇸 Roseville, California, United States

Local Institution - 001-850-J; 🇺🇸 Sacramento, California, United States

Local Institution - 001-850-D; 🇺🇸 Sacramento, California, United States

Local Institution - 001-840-A; 🇺🇸 San Diego, California, United States

Local Institution - 001-850-H; 🇺🇸 San Francisco, California, United States

Local Institution - 001-850-E; 🇺🇸 San Francisco, California, United States

Local Institution - 001-850-F; 🇺🇸 San Jose, California, United States

Local Institution - 001-850-A; 🇺🇸 San Leandro, California, United States

Local Institution - 001-850-I; 🇺🇸 Santa Clara, California, United States

Local Institution - 001-884-A; 🇺🇸 Solvang, California, United States

Local Institution - 001-850-G; 🇺🇸 Walnut Creek, California, United States

USOR - Rocky Mountain Cancer Centers - Aurora; 🇺🇸 Aurora, Colorado, United States

Local Institution - 001-872-H; 🇺🇸 Boulder, Colorado, United States

Local Institution - 001-872-E; 🇺🇸 Colorado Springs, Colorado, United States

Local Institution - 001-872-B; 🇺🇸 Denver, Colorado, United States

Local Institution - 001-951 - A; 🇺🇸 Denver, Colorado, United States

Local Institution - 001-951 - B; 🇺🇸 Denver, Colorado, United States

Local Institution - 001-872-A; 🇺🇸 Lakewood, Colorado, United States

Local Institution - 001-872-D; 🇺🇸 Littleton, Colorado, United States

Local Institution - 001-872-K; 🇺🇸 Lone Tree, Colorado, United States

Local Institution - 001-872-C; 🇺🇸 Longmont, Colorado, United States

Local Institution - 001-872-J; 🇺🇸 Parker, Colorado, United States

Local Institution - 001-872-F; 🇺🇸 Pueblo, Colorado, United States

Local Institution - 001-872-G; 🇺🇸 Pueblo, Colorado, United States

Local Institution - 001-872-I; 🇺🇸 Thornton, Colorado, United States

Local Institution - 001-929i; 🇺🇸 Altamonte Springs, Florida, United States

Boca Raton Clinical Research Associates, Inc.; 🇺🇸 Boca Raton, Florida, United States

Local Institution - 001-929c; 🇺🇸 Brandon, Florida, United States

Local Institution - 001-929g; 🇺🇸 Clearwater, Florida, United States

Local Institution - 001-926b; 🇺🇸 Daytona Beach, Florida, United States

Local Institution - 001-929b; 🇺🇸 Gainesville, Florida, United States

Local Institution - 001-929m; 🇺🇸 Lady Lake, Florida, United States

Local Institution - 001-929e; 🇺🇸 Largo, Florida, United States

Local Institution - 001-929n; 🇺🇸 Lecanto, Florida, United States

Local Institution - 001-929p; 🇺🇸 Ocala, Florida, United States

Local Institution - 001-929j; 🇺🇸 Orange City, Florida, United States

Local Institution - 001-929l; 🇺🇸 Orlando, Florida, United States

Local Institution - 001-929a; 🇺🇸 Saint Petersburg, Florida, United States

Local Institution - 001-929h; 🇺🇸 Spring Hill, Florida, United States

Local Institution - 001-926d; 🇺🇸 Stuart, Florida, United States

Local Institution - 001-929d; 🇺🇸 Tampa, Florida, United States

Local Institution - 001-929k; 🇺🇸 Tavares, Florida, United States

Local Institution - 001-929f; 🇺🇸 Trinity, Florida, United States

Local Institution - 001-926c; 🇺🇸 Vero Beach, Florida, United States

Local Institution - 001-926a; 🇺🇸 Wellington, Florida, United States

Local Institution - 001-929o; 🇺🇸 Winter Park, Florida, United States

Local Institution - 001-835-C; 🇺🇸 Austell, Georgia, United States

Local Institution - 001-835-E; 🇺🇸 Austell, Georgia, United States

Local Institution - 001-835-D; 🇺🇸 Carrollton, Georgia, United States

Local Institution - 001-835-F; 🇺🇸 Carrollton, Georgia, United States

Local Institution - 001-835-A; 🇺🇸 Cartersville, Georgia, United States

Local Institution - 001-835-B; 🇺🇸 Douglasville, Georgia, United States

University of Iowa; 🇺🇸 Iowa City, Iowa, United States

Local Institution - 001-881-B; 🇺🇸 Brandywine, Maryland, United States

Local Institution - 001-881-A; 🇺🇸 Silver Spring, Maryland, United States

Local Institution - 001-842-A; 🇺🇸 Farmington Hills, Michigan, United States

Local Institution - 001-838-F; 🇺🇸 Coon Rapids, Minnesota, United States

Local Institution - 001-838-E; 🇺🇸 Edina, Minnesota, United States

Local Institution - 001-875 - D; 🇺🇸 Edina, Minnesota, United States

Local Institution - 001-838-D; 🇺🇸 Maplewood, Minnesota, United States

Local Institution - 001-875 - A; 🇺🇸 Maplewood, Minnesota, United States

Local Institution - 001-838-C; 🇺🇸 Minneapolis, Minnesota, United States

Local Institution - 001-838-G; 🇺🇸 Minneapolis, Minnesota, United States

Local Institution - 001-822-A; 🇺🇸 Minneapolis, Minnesota, United States

Local Institution - 001-838-B; 🇺🇸 Saint Louis Park, Minnesota, United States

Local Institution - 001-838-A; 🇺🇸 Saint Paul, Minnesota, United States

Local Institution - 001-875 - B; 🇺🇸 Saint Paul, Minnesota, United States

Local Institution - 001-875 - C; 🇺🇸 Woodbury, Minnesota, United States

Local Institution - 001-544B; 🇺🇸 Omaha, Nebraska, United States

Local Institution - 001-544A; 🇺🇸 Omaha, Nebraska, United States

Local Institution - 001-860A; 🇺🇸 Henderson, Nevada, United States

Local Institution - 001-860C; 🇺🇸 Henderson, Nevada, United States

Local Institution - 001-860B; 🇺🇸 Henderson, Nevada, United States

Local Institution - 001-860E; 🇺🇸 Las Vegas, Nevada, United States

Local Institution - 001-860D; 🇺🇸 Las Vegas, Nevada, United States

Local Institution - 001-860F; 🇺🇸 Las Vegas, Nevada, United States

Local Institution - 001-833 - H; 🇺🇸 Columbus, Ohio, United States

Local Institution - 001-833 - C; 🇺🇸 Columbus, Ohio, United States

Local Institution - 001-833 - J; 🇺🇸 Columbus, Ohio, United States

Local Institution - 001-833 - A; 🇺🇸 Columbus, Ohio, United States

Local Institution - 001-833 - F; 🇺🇸 Columbus, Ohio, United States

Local Institution - 001-833 - D; 🇺🇸 Columbus, Ohio, United States

Local Institution - 001-833 - I; 🇺🇸 Columbus, Ohio, United States

Local Institution - 001-833 - B; 🇺🇸 Columbus, Ohio, United States

Local Institution - 001-833 - G; 🇺🇸 Columbus, Ohio, United States

Local Institution - 001-833 - E; 🇺🇸 Gahanna, Ohio, United States

Local Institution - 001-836-A; 🇺🇸 Kettering, Ohio, United States

Local Institution - 001-584; 🇺🇸 Tulsa, Oklahoma, United States

Local Institution - 001-586-A; 🇺🇸 Bend, Oregon, United States

Local Institution - 001-837-A; 🇺🇸 Bethlehem, Pennsylvania, United States

Local Institution - 001-801-G; 🇺🇸 Gallatin, Tennessee, United States

Local Institution - 001-801-A; 🇺🇸 Hendersonville, Tennessee, United States

Local Institution - 001-801-D; 🇺🇸 Hermitage, Tennessee, United States

Local Institution - 001-801-F; 🇺🇸 Murfreesboro, Tennessee, United States

Local Institution - 001-801-B; 🇺🇸 Nashville, Tennessee, United States

Local Institution - 001-801-E; 🇺🇸 Nashville, Tennessee, United States

Local Institution - 001-801-C; 🇺🇸 Nashville, Tennessee, United States

Local Institution - 001-888-B; 🇺🇸 Arlington, Texas, United States

Local Institution - 001-848a; 🇺🇸 Conroe, Texas, United States

Local Institution - 001-935A; 🇺🇸 Houston, Texas, United States

Local Institution - 001-935D; 🇺🇸 Kingwood, Texas, United States

Local Institution - 001-935B; 🇺🇸 Shenandoah, Texas, United States

Local Institution - 001-935C; 🇺🇸 Spring, Texas, United States

Local Institution - 001-935E; 🇺🇸 Tomball, Texas, United States

Local Institution - 001-882-A; 🇺🇸 Norfolk, Virginia, United States

ONeal Comprehensive Cancer Center at the University of Alabama at Birmingham; 🇺🇸 Birmingham, Alabama, United States

Alaska Oncology and Hematology; 🇺🇸 Anchorage, Alaska, United States

Mayo Clinic Arizona - Phoenix Campus; 🇺🇸 Phoenix, Arizona, United States

Local Institution - 001-807; 🇺🇸 Scottsdale, Arizona, United States

USOR - Arizona Oncology - Tucson - Rudasill; 🇺🇸 Tucson, Arizona, United States

Beverly Hills Cancer Center; 🇺🇸 Beverly Hills, California, United States

City of Hope - Duarte (Main Campus); 🇺🇸 Duarte, California, United States

Providence Medical Foundation - Virginia K. Crosson Cancer Center - Fullerton; 🇺🇸 Fullerton, California, United States

University of California San Diego Moores Cancer Center; 🇺🇸 La Jolla, California, United States

TRIO - Cancer and Blood Specialty Clinic; 🇺🇸 Los Alamitos, California, United States

Southern California Permanente Medical Group - Los Angeles Medical Center; 🇺🇸 Los Angeles, California, United States

Hoag Memorial Hospital Presbyterian - Newport Beach; 🇺🇸 Newport Beach, California, United States

University of California Irvine Medical Center; 🇺🇸 Orange, California, United States

California Cancer Associates for Research and Excellence (cCARE) - San Diego 4S Ranch; 🇺🇸 San Diego, California, United States

Ridley - Tree Cancer Center - Santa Barbara; 🇺🇸 Santa Barbara, California, United States

Kaiser Permanente - Vallejo Medical Center; 🇺🇸 Vallejo, California, United States

Valkyrie Clinical Trials; 🇺🇸 Los Angeles, California, United States

UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center; 🇺🇸 Aurora, Colorado, United States

Cancer Centers of Colorado - St. Marys Regional Hospital; 🇺🇸 Grand Junction, Colorado, United States

SCL Health - Saint Joseph Hospital Cancer Center; 🇺🇸 Lafayette, Colorado, United States

Yale Cancer Center; 🇺🇸 New Haven, Connecticut, United States

USOR - Medical Oncology Hematology Consultants; 🇺🇸 Newark, Delaware, United States

SCRI - Florida Cancer Specialists - South Region Research Office; 🇺🇸 Fort Myers, Florida, United States

Mayo Clinic - Jacksonville; 🇺🇸 Jacksonville, Florida, United States

Mount Sinai Comprehensive Cancer Center; 🇺🇸 Miami Beach, Florida, United States

Miami Cancer Institute; 🇺🇸 Miami, Florida, United States

Florida Cancer Affiliates - Ocala - Main; 🇺🇸 Ocala, Florida, United States

Mid Florida Cancer Centers - Orange City; 🇺🇸 Orange City, Florida, United States

Woodlands Medical Specialists; 🇺🇸 Pensacola, Florida, United States

SCRI - Florida Cancer Specialists - North Region Research Office; 🇺🇸 Saint Petersburg, Florida, United States

SCRI - Florida Cancer Specialists - East Region Research Office; 🇺🇸 West Palm Beach, Florida, United States

University Cancer & Blood Center (UCBC) - Athens; 🇺🇸 Athens, Georgia, United States

Northwest Georgia Oncology Centers Wellstar - Marietta; 🇺🇸 Marietta, Georgia, United States

Affiliated Oncologists - Millenium Medical Center - Chicago Ridge; 🇺🇸 Chicago Ridge, Illinois, United States

Local Institution - 001-828; 🇺🇸 Chicago, Illinois, United States

USOR - Illinois Cancer Specialists - Niles; 🇺🇸 Niles, Illinois, United States

Memorial Hospital; 🇺🇸 South Bend, Indiana, United States

University of Kansas Medical Center; 🇺🇸 Westwood, Kansas, United States

University of Kentucky; 🇺🇸 Lexington, Kentucky, United States

SCRI - Hematology Oncology Clinic - Baton Rouge; 🇺🇸 Baton Rouge, Louisiana, United States

MaineHealth Cancer Care - Biddeford; 🇺🇸 Biddeford, Maine, United States

Maryland Oncology Hematology - Columbia; 🇺🇸 Columbia, Maryland, United States

Dana-Farber Cancer Institute; 🇺🇸 Boston, Massachusetts, United States

Barbara Ann Karmanos Cancer Institute; 🇺🇸 Detroit, Michigan, United States

Henry Ford Health System; 🇺🇸 Detroit, Michigan, United States

USOR - Minnesota Oncology - Minneapolis Clinic; 🇺🇸 Minneapolis, Minnesota, United States

Masonic Cancer Center; 🇺🇸 Minneapolis, Minnesota, United States

Mayo Clinic - Rochester; 🇺🇸 Rochester, Minnesota, United States

Metro-Minnesota Community Oncology Research Consortium (MMCORC); 🇺🇸 Saint Louis Park, Minnesota, United States

Central Care Cancer Center - Bolivar; 🇺🇸 Bolivar, Missouri, United States

Goldschmidt Cancer Center; 🇺🇸 Jefferson City, Missouri, United States

Sisters of Charity of Leavenworth Health St. Marys; 🇺🇸 Billings, Montana, United States

Methodist Estabrook Cancer Center; 🇺🇸 Omaha, Nebraska, United States

University of Nebraska Medical Center; 🇺🇸 Omaha, Nebraska, United States

USOR - Comprehensive Cancer Centers of Nevada - Southeast Henderson; 🇺🇸 Henderson, Nevada, United States

New York Oncology Hematology - Albany Medical Center; 🇺🇸 Albany, New York, United States

Roswell Park Comprehensive Cancer Center; 🇺🇸 Buffalo, New York, United States

Local Institution - 001-832; 🇺🇸 Lake Success, New York, United States

Perlmutter Cancer Center - 34th Street; 🇺🇸 New York, New York, United States

Local Institution - 001-583; 🇺🇸 New York, New York, United States

Memorial Sloan Kettering Cancer Center - New York; 🇺🇸 New York, New York, United States

The Ohio State University College of Medicine; 🇺🇸 Columbus, Ohio, United States

SCRI - Mark H. Zangmeister Cancer Center; 🇺🇸 Columbus, Ohio, United States

Kettering Health Cancer Center - Main Campus; 🇺🇸 Kettering, Ohio, United States

University of North Carolina Hospitals; 🇺🇸 Chapel Hill, North Carolina, United States

The Christ Hospital; 🇺🇸 Cincinnati, Ohio, United States

FirstHealth Outpatient Cancer Center; 🇺🇸 Pinehurst, North Carolina, United States

University of Cincinnati Health Barrett Cancer Center; 🇺🇸 Cincinnati, Ohio, United States

Cleveland Clinic Lerner College of Medicine; 🇺🇸 Cleveland, Ohio, United States

Cancer Centers of Southwest Oklahoma - Leah M. Fitch Cancer Center; 🇺🇸 Lawton, Oklahoma, United States

Local Institution - 001-580; 🇺🇸 Oklahoma City, Oklahoma, United States

St. Charles Health System; 🇺🇸 Bend, Oregon, United States

Willamette Valley Cancer Institute and Research Center - Eugene; 🇺🇸 Eugene, Oregon, United States

Lehigh Valley Physician Group Hematology Oncology; 🇺🇸 Allentown, Pennsylvania, United States

Penn State Cancer Institute; 🇺🇸 Hershey, Pennsylvania, United States

USOR - Alliance Cancer Specialists - Media (Cancer Center at Riddle Memorial Hospital); 🇺🇸 Media, Pennsylvania, United States

USOR - Charleston Hematology Oncology Associates; 🇺🇸 Charleston, South Carolina, United States

Medical University of South Carolina; 🇺🇸 Charleston, South Carolina, United States

Tennessee Oncology - Nashville - Centennial Clinic - Medical Oncology; 🇺🇸 Nashville, Tennessee, United States

USOR - Texas Oncology Dallas Fort Worth West (DFWW) - Arlington South; 🇺🇸 Arlington, Texas, United States

USOR - Texas Oncology - Austin Central; 🇺🇸 Austin, Texas, United States

Mary Crowley Cancer Research - Medical City Hospital; 🇺🇸 Dallas, Texas, United States

USOR - Texas Oncology - Dallas Fort Worth (DFW) - Presbyterian Cancer Center Dallas; 🇺🇸 Dallas, Texas, United States

USOR - Texas Oncology - Dallas Fort Worth (DFW) - Baylor Charles A. Sammons Cancer Center; 🇺🇸 Dallas, Texas, United States

USOR - Texas Oncology Northeast Texas - Denison; 🇺🇸 Denison, Texas, United States

Texas Oncology - Dallas Fort Worth (DFW) - Fort Worth; 🇺🇸 Fort Worth, Texas, United States

Oncology Consultants - Texas Medical Center; 🇺🇸 Houston, Texas, United States

University of Texas MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States

Local Institution - 001-999; 🇺🇸 Irving, Texas, United States

Lumi Research; 🇺🇸 Kingwood, Texas, United States

USOR - Texas Oncology - Midland Allison Cancer Center; 🇺🇸 Midland, Texas, United States

START Center for Cancer Care; 🇺🇸 San Antonio, Texas, United States

Texas Oncology - Sugar Land; 🇺🇸 Sugar Land, Texas, United States

Texas Oncology - Northeast Texas Cancer and Research Institute - Tyler; 🇺🇸 Tyler, Texas, United States

Texas Oncology - Waco; 🇺🇸 Waco, Texas, United States

Local Institution - 001-919; 🇺🇸 Fairfax, Virginia, United States

NEXT Virginia; 🇺🇸 Fairfax, Virginia, United States

Hematology Oncology Associates of Fredericksburg; 🇺🇸 Fredericksburg, Virginia, United States

USOR - Virginia Oncology Associates - Newport News; 🇺🇸 Newport News, Virginia, United States

Virginia Cancer Institute - West End; 🇺🇸 Richmond, Virginia, United States

Fred Hutchinson Cancer Research Center; 🇺🇸 Seattle, Washington, United States

USOR - Northwest Cancer Specialists, P.C. dba Compass Oncology - Vancouver Cancer Center; 🇺🇸 Vancouver, Washington, United States

University Wisconsin Carbone Cancer Center; 🇺🇸 Madison, Wisconsin, United States

PanOncology Trials - Rio Piedras Medical Center; 🇵🇷 San Juan, Puerto Rico